KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025)

Aquestive Therapeutics (AQST) has 3 years of Capital Leases data on record, last reported at $122000.0 in Q3 2025.

  • For Q3 2025, Capital Leases fell 20.26% year-over-year to $122000.0; the TTM value through Sep 2025 reached $122000.0, down 20.26%, while the annual FY2024 figure was $146000.0, 15.61% down from the prior year.
  • Capital Leases reached $122000.0 in Q3 2025 per AQST's latest filing, down from $130000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $173000.0 in Q4 2023 and bottomed at $122000.0 in Q3 2025.
  • Average Capital Leases over 3 years is $148625.0, with a median of $149500.0 recorded in 2024.
  • Peak YoY movement for Capital Leases: dropped 15.61% in 2024, then dropped 20.26% in 2025.
  • A 3-year view of Capital Leases shows it stood at $173000.0 in 2023, then fell by 15.61% to $146000.0 in 2024, then dropped by 16.44% to $122000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $122000.0 in Q3 2025, $130000.0 in Q2 2025, and $138000.0 in Q1 2025.